![]() Of the CLTI patients, 47% had diabetes, 13% had renal insufficiency, mean lesion length was 130.2 ± 92.7 mm, and 64% of lesions were occluded.Īn independent clinical events committee adjudicated major adverse events (MAEs), including death and potential device-related events.Īt VIVA, Dr. Of the claudicant patients, 34% had diabetes, 7% had renal insufficiency, mean lesion length was 126.3 ± 92.9 mm, and 54% of lesions were occluded. The VIVA announcement stated that the MIMICS-3D registry enrolled 507 patients treated with BioMimics 3D at 23 sites: 76% were claudicants (Rutherford class 1-3) and 24% had chronic limb-threatening ischemia (CLTI Rutherford class 4-6). Parikh, MD, presented the 2-year data from the MIMICS-3D study during a late-breaking clinical trials session at the VIVA 2021, the annual Vascular InterVentional Advances meeting held October 4-7 in Las Vegas, Nevada. The 3D helical centerline provides biomechanical compatibility and swirling blood flow to elevate wall shear stress to limit intimal hyperplasia. October 6, 2021-The VIVA Foundation announced that the BioMimics 3D nitinol stent (Veryan Medical), which features a three-dimensional (3D) helical centerline, was evaluated in the MIMICS-3D European registry to treat patients with longer, more complex lesions than previously studied.Īccording to VIVA, BioMimics 3D is designed to provide optimal radial support, flexibility, durability, and delivery accuracy for femoropopliteal intervention. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |